IQVIA Holdings (IQV) Maintains Momentum Amid +3.4% Monthly Gain and Raised Guidance
Key Takeaways
- IQV shares closed at $270.37, up roughly 3.4% over the trailing 30 days, extending a multi-month climb from the mid-$170s reached in June.
- Second-quarter 2026 results beat expectations, with revenue of $4.37 billion (up 8.7% year over year) and adjusted diluted EPS of $3.15.
- Company-wide organic growth accelerated to 6% year over year — about three times the rate reported a year earlier.
- R&D Solutions net new bookings rose about 19% year over year to $3.15 billion, supporting a book-to-bill ratio of 1.22 and a backlog of roughly $34.2 billion.
- Management raised full-year 2026 guidance for revenue, adjusted EBITDA, and adjusted diluted EPS, citing broad-based demand and AI traction.
Current Market Snapshot
IQV shares have shown an upward bias through late summer and into autumn, consolidating in the upper $250s to low $270s after a sharp advance following the second-quarter earnings release. The stock gained about 3.4% over the last 30 days, a modest near-term move that still reflects a much stronger multi-month trend, with shares up roughly 40% since late June. This performance points to improving sentiment in the life-sciences services sector and the company’s accelerating bookings momentum.
Sector positioning continues to matter here. As a leading clinical research organization and healthcare data provider, IQVIA Holdings sits at the intersection of pharmaceutical R&D outsourcing, real-world data, and applied artificial intelligence. I see it as a leveraged way for investors to gain exposure to biotech funding recovery and increased outsourcing by large pharmaceutical sponsors, while remaining mindful of trial pricing and foreign-exchange sensitivities. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
IQVIA Holdings (IQV) Business Overview and Competitive Position
IQVIA Holdings Inc. provides clinical research services, commercial insights, and healthcare intelligence to the life-sciences and healthcare industries. With approximately 93,000 employees across more than 100 countries, the company supports biotech, pharmaceutical, and medical-device clients in developing and commercializing treatments.
Effective January 1, 2026, IQV simplified its reporting structure into two primary segments: R&D Solutions, covering clinical trial management and related research services, and Commercial Solutions, which includes technology, analytics, real-world insights, and patient-engagement offerings. Competitive strengths include scale, proprietary data assets through its Connected Intelligence platform, and Healthcare-grade AI capabilities focused on privacy, regulatory compliance, and patient safety. From what I see, investors track IQV closely because its results serve as a barometer for global pharmaceutical R&D spending and the broader adoption of data-driven healthcare analytics.
Recent Developments Driving IQV
The most significant recent catalyst came with the second-quarter 2026 report released on July 28. Revenue reached $4.37 billion, above consensus estimates of roughly $4.30 billion, while adjusted diluted EPS of $3.15 exceeded expectations. Adjusted EBITDA came in at $994 million. Management described the quarter as broad-based, with organic growth accelerating to 6% and stronger operational execution across both segments.
Bookings stood out as particularly encouraging. R&D Solutions net new bookings of $3.15 billion represented a roughly 19% year-over-year increase, producing a book-to-bill ratio of 1.22 and lifting twelve-month net new bookings to about $11.3 billion. On the strength of these results, the company raised its full-year 2026 outlook to revenue of $17.275 billion to $17.475 billion, adjusted EBITDA of $4.00 billion to $4.05 billion, and adjusted diluted EPS of $12.80 to $13.00.
Artificial intelligence has featured repeatedly in management commentary. The company has highlighted healthcare-grade AI agents, expanded analytics and consulting pipelines, and collaboration with technology leaders such as NVIDIA on platforms aimed at accelerating trial execution and analytics. Management has noted that AI adoption is generating incremental demand rather than displacing services. A more supportive funding environment for emerging biopharma companies, together with a rising number of new drug launches, has also supported demand.
2026 Outlook and What Investors Should Watch
Looking ahead, several factors will shape IQV’s trajectory through the rest of 2026. The pace of R&D Solutions bookings and backlog conversion remains the key demand indicator, as newly awarded contracts convert to revenue over multiple years. Analysts will also follow the monetization of AI-enabled offerings across clinical and commercial segments, along with the integration of recent acquisitions.
On the financial side, investors should monitor adjusted EBITDA margin progression, foreign-exchange effects, and the company’s leverage position, which management has been managing alongside ongoing share repurchases. Macro-level risks include potential shifts in biotech funding, pricing pressure in the competitive CRO market, and regulatory developments affecting pharmaceutical research and reimbursement. IQV’s next quarterly report is expected in early November, and its updated guidance will provide a clearer view of whether recent momentum in bookings and organic growth can be sustained. One thing that stands out is how consistently the company has executed on its growth targets so far this year.
Exploring Tickeron’s Trending AI Robots
I often turn to Tickeron’s tools when evaluating how different stocks are behaving across automated strategies. The Trending AI Robots page curates top-performing bots based on recent results, allowing users to compare approaches without sifting through every available option. It offers a practical way to observe how these systems interpret shifting market conditions across various timeframes and patterns. For those interested in data-driven trading tools, the Trending AI Robots page serves as a useful starting point for further exploration.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
Momentum Indicator for IQV turns negative, indicating new downward trend
IQV saw its Momentum Indicator move below the 0 level on October 01, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 75 similar instances where the indicator turned negative. In 51 of the 75 cases, the stock moved further down in the following days. The odds of a decline are at 68%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for IQV moved out of overbought territory on September 04, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 44 similar instances where the indicator moved out of overbought territory. In 28 of the 44 cases, the stock moved lower in the following days. This puts the odds of a move lower at 64%.
The Moving Average Convergence Divergence Histogram (MACD) for IQV turned negative on September 01, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 42 similar instances when the indicator turned negative. In 25 of the 42 cases the stock turned lower in the days that followed. This puts the odds of success at 60%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IQV declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 64%.
Bullish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
Following a +1.38% 3-day Advance, the price is estimated to grow further. Considering data from situations where IQV advanced for three days, in 189 of 302 cases, the price rose further within the following month. The odds of a continued upward trend are 63%.
IQV may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 117 of 228 cases where IQV Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 51%.
Fundamental Analysis (Ratings)
The Tickeron Seasonality Score of 16 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 18 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 39 (best 1 - 100 worst), indicating steady price growth. IQV’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 43 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 65 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (7.225) is normal, around the industry mean (72.578). P/E Ratio (33.703) is within average values for comparable stocks, (146.993). Projected Growth (PEG Ratio) (0.985) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.001) among similar stocks. P/S Ratio (2.693) is also within normal values, averaging (9.775).
The Tickeron Profit vs. Risk Rating rating for this company is 98 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IQV’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 91, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a provider of biopharmaceutical development services and commercial outsourcing services
Industry MedicalSpecialties
Advertisement